钆塞酸二钠增强T1 mapping在自身免疫性肝炎纤维化与炎症分期中有作用吗?一项前瞻性研究
前瞻性纳入33例自身免疫性肝炎患者,在活检前3个月内行钆塞酸二钠增强T1 mapping,评估其预测纤维化分期和炎症活动的价值。增强后20分钟T1(AUC 0.822)及数学公式Adjusted T1 Liver B(AUC 0.815)可区分进展期(F3-F4)与非进展期(F0-F2)纤维化,但均不能区分显著纤维化(F2-F4)或较高炎症分级(PPA 2-4),也未优于平扫T1测量。
要点
- 增强后20分钟T1鉴别进展期纤维化(F3-F4 vs F0-F2)AUC 0.822(95%CI 0.674-0.970)。
- 公式Adjusted T1 Liver B鉴别进展期纤维化AUC 0.815(95%CI 0.660-0.970)。
- 增强后T1 mapping未能区分显著纤维化(F2-F4)或较高炎症分级(PPA 2-4),且未优于平扫T1(p>0.05)。
核心结论
- 在自身免疫性肝炎中,标准肝脏MRI方案中的钆塞酸二钠增强后T1 mapping可识别进展期纤维化,与组织病理学金标准相关性好,但未优于更简单的平扫T1测量,也不能可靠区分显著纤维化或重度炎症。
研究设计与样本
- 前瞻性研究,纳入33例自身免疫性肝炎患者,在活检前最多3个月内行多参数肝脏MRI方案并采集钆塞酸二钠增强后T1 mapping,以Metavir(F0-F4)纤维化分期和Desmet炎症分级(PPA 0-4)为参考标准。
诊断标准与关键数值
- 增强后20分钟T1区分进展期(F3-F4)与非进展期(F0-F2)纤维化AUC 0.822(95%CI 0.674-0.970);公式Adjusted T1 Liver B区分进展期与非进展期纤维化AUC 0.815(95%CI 0.660-0.970);所有MRI参数均未能区分显著纤维化(F2-F4)或较高炎症分级(PPA 2-4);增强后T1 mapping未优于平扫T1测量(p>0.05)。
临床应用与阅片要点
- 作者结论提示,在自身免疫性肝炎的标准肝脏MRI方案中,增强后T1 mapping可识别进展期纤维化,但未优于平扫T1测量,也不能可靠区分显著纤维化或重度炎症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Autoimmune hepatitis (AIH) is an immune-mediated liver disease that may progress to cirrhosis if untreated. Liver biopsy is the gold standard for assessing fibrosis and inflammation, but it is invasive and prone to sampling errors. This prospective study evaluated whether MRI T1 mapping with gadoxetic acid (Gd-EOB-DTPA) can noninvasively predict fibrosis stage and inflammatory activity in AIH. We compared several post-contrast T1 mapping-derived formulas to determine accuracy in detecting significant (F2-F4) and advanced (F3-F4) fibrosis and higher inflammatory activity (PPA 2-4).
MATERIALS & METHODS: Over three years, 33 AIH patients underwent a multiparametric liver MRI protocol with post-Gd-EOB-DTPA T1 mapping. Biopsies were performed up to three months prior. We measured standard pre- and post-contrast T1, adjusted liver T1 formulas, and hepatic uptake rates (Khep). Independent t-tests, Mann-Whitney U-tests, and ROC curves compared these indices against Metavir (F0-F4) and Desmet inflammatory grading (PPA 0-4).
RESULTS: Post-contrast T1 at 20 min (AUC 0.822; 95% CI 0.674-0.970) and a mathematical formula (Adjusted T1 Liver B) (AUC 0.815; 95% CI 0.660-0.970) distinguished advanced (F3-F4) from non-advanced (F0-F2) fibrosis. However, none of the MRI-based parameters differentiated significant fibrosis (F2-F4) or higher inflammatory grades (PPA 2-4) from lower ones. Post-contrast T1 mapping did not outperform simpler pre-contrast T1 measurements (p > 0.05).
CONCLUSION: In AIH, post-Gd-EOB-DTPA T1 mapping within a standard liver MRI protocol can identify advanced fibrosis, correlating well with the histopathological gold standard. However, it does not outperform simpler pre-contrast T1 measurements or reliably distinguish significant fibrosis or severe inflammation.
引用
- Torres US, Gomes NBN, Caiado AHM, et al. Does Gd-EOB-DTPA-enhanced T1 mapping have a role in the staging of fibrosis and inflammation in autoimmune hepatitis? A prospective study. Abdom Radiol (NY). 2025. PMID: 40689953. doi:10.1007/s00261-025-05129-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。